Jiangsu-based HOB Biotech Group Corp., Ltd (SHA: 688656) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its MM09 sublingual spray. The product is intended to target indications such as mild to moderate asthma and allergic rhinitis/nasal conjunctivitis, with a focus on allergies to house dust and dust mites.
In September 2023, HOB Bio in-licensed 12 sublingual spray desensitizers from Spanish company Inmunotek, which were introduced to the Lecheng pilot zone in Hainan. The desensitizer series, including the MM09 sublingual spray, have been utilized as clinically urgent imported medical devices in the region under the “first pilot, first trial” policy since last September. This initiative has preliminarily demonstrated the safety and patient acceptance of these products.- Flcube.com
